{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:36:52Z","timestamp":1787564212555,"version":"build-2736575974"},"reference-count":23,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2004,7,19]],"date-time":"2004-07-19T00:00:00Z","timestamp":1090195200000},"content-version":"vor","delay-in-days":200,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chirality"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The present study investigates the urinary excretion of the enantiomers of (+)\u2010 and (\u2013)\u2010albendazole sulfoxide (ASOX) and albendazole sulfone (ASON) in 12 patients with neurocysticercosis treated with albendazole for 8 days (7.5 mg\/kg\/12 h). Serial blood samples (0\u201312 h) and urine (three periods of 8 h) were collected after administration of the last dose of albendazole. Plasma and urine (+)\u2010ASOX, (\u2013)\u2010ASOX, and ASON metabolites were determined by HPLC using a chiral phase column (Chiralpak AD) with fluorescence detection. The pharmacokinetic parameters (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05) for (+)\u2010ASOX, (\u2013)\u2010ASOX, and ASON metabolites are reported as means (95% CI); amount excreted (Ae) = 3.19 (1.53\u20134.85) vs. 0.72 (0.41\u20131.04) vs. 0.08 (0.03\u20130.13) mg; plasma concentration\u2010time area under the curve, AUC\n                    <jats:sup>0\u201324<\/jats:sup>\n                    = 3.56 (0.93\u20136.18) vs. 0.60 (0.12\u20131.08) vs. 0.38 (0.20\u20130.55) \u03bcg.h\/ml, and renal clearance Cl\n                    <jats:sub>R<\/jats:sub>\n                    = 1.20 (0.66\u20131.73) vs. 2.72 (0.39\u20135.05) vs. 0.25 (0.13\u20130.37) l\/h. Sulfone formation capacity, expressed as the Ae ratio ASON\/ASOX + ASON, was 2.21 (1.43\u20132.99). These data point to enantioselectivity in the renal excretion of ASOX as a complementary mechanism to the metabolism responsible for the plasma accumulation of (+)\u2010ASOX. The results also suggest that the metabolite ASON is partially eliminated as a reaction product of the subsequent metabolism.\n                    <jats:italic>Chirality 16:520\u2013525, 2004<\/jats:italic>\n                    . \u00a9 2004 Wiley\u2010Liss, Inc.\n                  <\/jats:p>","DOI":"10.1002\/chir.20071","type":"journal-article","created":{"date-parts":[[2004,7,19]],"date-time":"2004-07-19T15:01:49Z","timestamp":1090249309000},"page":"520-525","source":"Crossref","is-referenced-by-count":18,"title":["Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis"],"prefix":"10.1002","volume":"16","author":[{"given":"V.L.","family":"Lanchote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.M.","family":"Takayanagui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.H.","family":"Mateus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,7,19]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.4.1.129"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.4.747-756.2002"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00170.x"},{"key":"e_1_2_1_5_2","first-page":"758","article-title":"Albendazole sulfonation by rat liver cytochrome P\u2010450c","volume":"246","author":"Souhaili\u2010El Amri H","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498259509061863"},{"key":"e_1_2_1_7_2","first-page":"160","article-title":"Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide\u2010containing and cytochrome P450\u2010dependent monoxygenases from rat liver microsomes","volume":"23","author":"Moroni P","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498259109039463"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-636X(1999)11:3<218::AID-CHIR8>3.0.CO;2-G"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/chir.530020306"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0034-5288(91)90095-6"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00278590"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00540964"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1992.tb03783.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199702000-00009"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200206000-00003"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01634.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(98)00082-6"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(98)00497-6"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(02)00382-5"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1522-2683(200109)22:15<3263::AID-ELPS3263>3.0.CO;2-4"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(02)00665-7"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00608219"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199302000-00009"}],"container-title":["Chirality"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fchir.20071","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/chir.20071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T19:48:43Z","timestamp":1695930523000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/chir.20071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1002\/chir.20071"],"URL":"https:\/\/doi.org\/10.1002\/chir.20071","archive":["Portico"],"relation":{},"ISSN":["0899-0042","1520-636X"],"issn-type":[{"value":"0899-0042","type":"print"},{"value":"1520-636X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}